Cipla Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7hspxyhy3jqpyjf3d1awpr2l.pdf

Key Takeaways


Lanreotide: The Supply-Demand Mismatch

Umang Vohra: “So Lanreotide is, I think there are two things that are happening. One is as we are expanding capacity, we have to reconfigure, the partner has to reconfigure the lines. I think some part of it is that. Some part of it is also that there is more demand than we anticipated. So I think it’s a mixture of both.”

One India: Seasonal Softness Masks Chronic Strength

Umang Vohra: “Unlike the acute season, this is not solely a seasonal trigger. It is also the impact of pollution in the air. It is also an impact of allergens and pollen.”

US Business: Base Holds as Lanreotide Swings


Africa & EMEU: Growth with Margin Discipline

Ashish Adukia: “No, we can assume this to be the base. There will be no de-growth, I would say. But anyways, like we always have said, the focus on Africa will always be margin for us because it is margin dilutive on an overall basis.”

Margins & Cost Structure


Regulatory & Pipeline Milestones

Umang Vohra: “Sema generic we will be participating and I think hopefully we will be amongst the first wave of people to enter in India.”

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin24.5% to 25.5% for the full yearFY25
Lanreotide supply resolutionIssues resolved; sharp recovery beginsEnd of Q3 FY25, recovery from Q4
Lanreotide Q4 recovery ceilingBounce-back will not exceed Q2 levelsQ4 FY25
Generic Advair filingFile by end of calendar yearCY24 end
Generic Advair launchApproval and launchH1 FY26
Symbicort and Qvar launchTimeline unchangedFY27
One Africa quarterly base₹800 crore run rate, no de-growth, 5–10% growthOngoing
China facility suppliesStart supplies from China plantFY25
R&D spend increaseAnother 20% increase expectedCY25
Goa facility remediationTimelines committed to FDA on key aspectsSix months to one year

Key Metrics

MetricQ2 FY25
Revenue₹7,051 cr, +9% YoY (adjusted for QCIL divestment)
EBITDA margin26.7%, highest ever quarterly reported EBITDA margin, up ~70 bps YoY and 111 bps QoQ
Gross margin67.6%, 159 bps above last year, driven by better mix
Profit after tax₹1,303 cr, 18.5% of sales, effective tax rate at 27%
R&D spend₹385 cr, 5.5% of revenue, +2% YoY
Total expenses₹2,882 cr, includes employee and other expenses
Net cash₹7,950 cr, with debt including lease liabilities at ₹461 cr
ROCE30%+, on an annualized basis
FY25 EBITDA margin guidance24.5% to 25.5%, unchanged
One India revenue growth5% YoY, impacted by slow acute season
North America revenue$237 million, supported by differentiated portfolio traction
One Africa revenue growth22%, with South Africa delivering similar growth in local currency
EMEU revenue growth18% in US dollar terms, pickup in DTM and B2B categories
Consumer Health revenue growth20%+, with operating profitability consistent at 15%
Albuterol market share19%, enhanced during the quarter
Lanreotide franchise market share35%, reached during the quarter as per IQVIA MAT-24
US base business price erosion~10% YoY blended, 3% to 5% QoQ
Chronic therapy share61.5% of branded prescription, as per IQVIA MAT September '24
Field force size8,700 people